CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-14-00453
Health/Science/Disease Category:
Relapsed Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkins Lymphoma (NHL)
Short Name:
TACL Temsirolimus ALL/NHL study
Full Title of Study:
T2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Phase/Type of Study:
Phase I drug treatment
Purpose of Research:
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
Eligibility:
Age 1 to 21 with leukemia (ALL) or NHL that has returned after an initial response to treatment
Time Commitment/Requirements:
If the disease is stable or responding, up to 8 cycles of therapy for up to 1 year.
Primary Investigator:
Dr. Paul S. Gaynon
Coordinator Contact Name:
Ellynore Florendo, CCRC or Meg Fender, CRC -III
Phone Number:
323-361-5429
Email:
TACL@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT01614197